SG11201508727WA - Purification of polysaccharide protein conjugates - Google Patents
Purification of polysaccharide protein conjugatesInfo
- Publication number
- SG11201508727WA SG11201508727WA SG11201508727WA SG11201508727WA SG11201508727WA SG 11201508727W A SG11201508727W A SG 11201508727WA SG 11201508727W A SG11201508727W A SG 11201508727WA SG 11201508727W A SG11201508727W A SG 11201508727WA SG 11201508727W A SG11201508727W A SG 11201508727WA
- Authority
- SG
- Singapore
- Prior art keywords
- purification
- protein conjugates
- polysaccharide protein
- polysaccharide
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2201CH2013 | 2013-05-20 | ||
| PCT/IB2014/061456 WO2014188313A1 (en) | 2013-05-20 | 2014-05-15 | Purification of polysaccharide protein conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201508727WA true SG11201508727WA (en) | 2015-11-27 |
Family
ID=51933026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201508727WA SG11201508727WA (en) | 2013-05-20 | 2014-05-15 | Purification of polysaccharide protein conjugates |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9782468B2 (en) |
| EP (1) | EP2999709A4 (en) |
| JP (1) | JP2016526037A (en) |
| KR (1) | KR20160009069A (en) |
| CN (1) | CN105431446A (en) |
| AU (1) | AU2014270076A1 (en) |
| BR (1) | BR112015029051A2 (en) |
| CA (1) | CA2910119A1 (en) |
| MX (1) | MX2015015516A (en) |
| PH (1) | PH12015502515A1 (en) |
| RU (1) | RU2015145238A (en) |
| SG (1) | SG11201508727WA (en) |
| WO (1) | WO2014188313A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506113D0 (en) * | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| US11162880B2 (en) | 2015-11-09 | 2021-11-02 | University Of Notre Dame Du Lac | Particle size purification method and devices |
| KR102204927B1 (en) * | 2016-07-25 | 2021-01-19 | 에스케이바이오사이언스(주) | Method for quality evaluation of capsular polysacchride-protein conjugate vaccine |
| CN109890413B (en) | 2016-09-02 | 2024-04-16 | 赛诺菲巴斯德股份有限公司 | Neisseria meningitidis vaccine |
| KR102472936B1 (en) * | 2017-07-05 | 2022-11-30 | 인벤트프라이즈 엘엘씨 | Polysaccharide Purification for Vaccine Manufacturing Using Soluble Enzymes, Tangential Flow Filtration, and Multimodal Chromatography |
| US10702596B2 (en) | 2017-07-05 | 2020-07-07 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| GB201711637D0 (en) * | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN108676829A (en) * | 2018-02-09 | 2018-10-19 | 中国医学科学院医学生物学研究所 | A method of removal acellular pertussis components endotoxin in vaccine |
| US20220306685A1 (en) * | 2019-06-07 | 2022-09-29 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
| RU2770877C1 (en) * | 2021-04-08 | 2022-04-22 | Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" | Method of producing antigenic conjugated substance of haemophilic type b microbe for creating vaccine preparations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
| SE9700769D0 (en) | 1997-03-04 | 1997-03-04 | Pharmacia Biotech Ab | Matrices for separation and separation that utilize the matrices |
| US6284250B1 (en) | 1998-02-05 | 2001-09-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
| SE0202551D0 (en) | 2002-08-27 | 2002-08-27 | Amersham Biosciences Ab | Chromatographic two-layer particles |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20080207487A1 (en) * | 2006-11-02 | 2008-08-28 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| JP5643642B2 (en) | 2007-07-25 | 2014-12-17 | ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー | Separation matrix |
| CN101939094B (en) | 2008-02-05 | 2013-11-20 | 通用电气健康护理生物科学股份公司 | Method for production of separation media |
| EP2268393A4 (en) | 2008-04-22 | 2013-08-14 | Ge Healthcare Bio Sciences Ab | Chromatography medium |
| US20110155668A1 (en) | 2008-07-08 | 2011-06-30 | Ge Healthcare Bio-Sciences Ab | Separation medium for chromatography of various biomolecules |
| US20110142863A1 (en) * | 2009-12-16 | 2011-06-16 | Millipore Corporation | Flow through purification processes for large biomolecules |
| EP2560738B8 (en) | 2010-04-23 | 2019-09-25 | Serum Institute of India Private Limited | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
-
2014
- 2014-05-15 EP EP14800254.6A patent/EP2999709A4/en not_active Withdrawn
- 2014-05-15 JP JP2016514504A patent/JP2016526037A/en active Pending
- 2014-05-15 WO PCT/IB2014/061456 patent/WO2014188313A1/en active Application Filing
- 2014-05-15 AU AU2014270076A patent/AU2014270076A1/en not_active Abandoned
- 2014-05-15 SG SG11201508727WA patent/SG11201508727WA/en unknown
- 2014-05-15 KR KR1020157035970A patent/KR20160009069A/en not_active Application Discontinuation
- 2014-05-15 BR BR112015029051A patent/BR112015029051A2/en not_active IP Right Cessation
- 2014-05-15 RU RU2015145238A patent/RU2015145238A/en not_active Application Discontinuation
- 2014-05-15 CA CA2910119A patent/CA2910119A1/en not_active Abandoned
- 2014-05-15 US US14/785,247 patent/US9782468B2/en not_active Expired - Fee Related
- 2014-05-15 CN CN201480028976.8A patent/CN105431446A/en active Pending
- 2014-05-15 MX MX2015015516A patent/MX2015015516A/en unknown
-
2015
- 2015-11-03 PH PH12015502515A patent/PH12015502515A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015502515A1 (en) | 2016-03-28 |
| US20160067325A1 (en) | 2016-03-10 |
| BR112015029051A2 (en) | 2017-07-25 |
| US9782468B2 (en) | 2017-10-10 |
| WO2014188313A1 (en) | 2014-11-27 |
| KR20160009069A (en) | 2016-01-25 |
| AU2014270076A1 (en) | 2015-11-12 |
| JP2016526037A (en) | 2016-09-01 |
| CN105431446A (en) | 2016-03-23 |
| MX2015015516A (en) | 2016-09-07 |
| EP2999709A1 (en) | 2016-03-30 |
| CA2910119A1 (en) | 2014-11-27 |
| EP2999709A4 (en) | 2016-12-07 |
| RU2015145238A (en) | 2017-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217499A1 (en) | Polymeric forms of h-nox proteins h-nox | |
| HK1219964A1 (en) | Continuous purification of therapeutic proteins | |
| IL244816A0 (en) | Protein-polymer-drug conjugates | |
| IL245009A0 (en) | Protein-polymer-drug conjugates | |
| SG11201508727WA (en) | Purification of polysaccharide protein conjugates | |
| GB201520943D0 (en) | Novel linker and preparation method thereof | |
| EP2970511A4 (en) | Insulin-incretin conjugates | |
| SG11201505198WA (en) | Protein purification methods | |
| SG11201603028SA (en) | Purification of proteins | |
| SG11201605260VA (en) | Var2csa-drug conjugates | |
| GB201317928D0 (en) | Molecule | |
| SG11201505204VA (en) | Protein purification process | |
| EP2992992A4 (en) | Different-material joint | |
| EP2968381A4 (en) | Sugar-linker-drug conjugates | |
| EP3060578A4 (en) | Antibody purification | |
| IL268868B (en) | Novel method of protein purification | |
| HK1219961A1 (en) | Human anti-ifn-alpha antibodies | |
| GB201314411D0 (en) | Peptide conjugates | |
| EP2929915A4 (en) | Body builder | |
| GB201308057D0 (en) | Protein | |
| PL3016977T3 (en) | Human anti-il-32 antibodies | |
| GB201302878D0 (en) | Modified igG molecules | |
| IL241248A0 (en) | Enhanced expression of picornavirus proteins | |
| HK1204916A1 (en) | Pharmaceutical application of anhydroicaritin | |
| HUE050547T2 (en) | Oligosaccharide conjugates and methods of use |